These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10760702)

  • 1. [Current biological markers of cutaneous melanoma progression].
    Stoitchkov K; Le Bricon T
    Ann Biol Clin (Paris); 2000; 58(2):157-65. PubMed ID: 10760702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Laboratory markers of melanoma progression].
    Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
    Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
    Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
    Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
    Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
    Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival.
    Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P
    Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour microdissemination and survival in metastatic melanoma.
    Schrader AJ; Probst-Kepper M; Grosse J; Kunter U; Franzke A; Sel S; Atzpodien E; Buer J
    Anticancer Res; 2000; 20(5B):3619-24. PubMed ID: 11131671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
    Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
    Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients.
    Baldi A; Dragonetti E; Battista T; Groeger AM; Esposito V; Baldi G; Santini D
    Anticancer Res; 2000; 20(5C):3923-8. PubMed ID: 11268478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circulating prognosis markers in melanoma: proteomic profiling and clinical studies].
    Solassol J; Guillot B; Maudelonde T
    Ann Biol Clin (Paris); 2011; 69(2):151-7. PubMed ID: 21464007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods of detection of circulating melanoma cells: a comparative overview.
    Nezos A; Msaouel P; Pissimissis N; Lembessis P; Sourla A; Armakolas A; Gogas H; Stratigos AJ; Katsambas AD; Koutsilieris M
    Cancer Treat Rev; 2011 Jun; 37(4):284-90. PubMed ID: 21106295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.
    Hoon DS; Bostick P; Kuo C; Okamoto T; Wang HJ; Elashoff R; Morton DL
    Cancer Res; 2000 Apr; 60(8):2253-7. PubMed ID: 10786692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
    Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
    Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
    Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
    Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.